B.R.A.I.N. Biotechnology Research and Information Network AG (DE:BNN)
XETRA:BNN
Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.50
€0.00(0.00%)
At close: 4:00 PM EST
€2.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.81 - €3.89
Previous CloseN/A
Volume750.00
Average Volume (3M)10.93K
Market Cap
€54.84M
Enterprise Value€104.79M
Total Cash (Recent Filing)€6.32M
Total Debt (Recent Filing)€24.03M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,847,494
10 Day Avg. Volume22,707
30 Day Avg. Volume10,926
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)€55.49M
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementAn improved gross margin in 2025 indicates better unit economics or cost control at the production level. If sustained, higher gross margins can provide more room to invest in R&D or commercial efforts, helping the company progress toward eventual operating leverage and improved long-term profitability.
Free Cash Flow TrendLess-negative free cash flow in 2025 shows the company is reducing its cash consumption trajectory. A continuing improvement in FCF reduces reliance on dilutive financing, lengthens runway, and supports strategic investments, making the firm's funding profile more durable over the medium term.
Sector ExposureOperating in biotechnology places the company in a sector with structural demand for innovation and long product development cycles. This positioning supports long-term opportunities for partnerships, licensing, or breakthroughs that can materially change revenue prospects if R&D execution succeeds.
Bears Say
Persistent LossesOngoing net losses indicate the business has not yet achieved operating profitability. Persistent deficits erode retained capital, constrain reinvestment, and require external funding. Without durable path to profit, long-term viability depends on continued financing or structural business improvement.
Negative Cash GenerationConsistent negative operating and free cash flow show the company consumes cash to run operations. This structural cash burn increases refinancing needs and dilution risk, forcing management to prioritize capital raises over long-term investments unless cash conversion reverses sustainably.
Weakened Balance SheetA materially weaker 2025 balance sheet with higher leverage and much lower equity heightens refinancing and dilution risk. Elevated financial leverage limits flexibility, increases fixed obligations, and can restrict strategic options if market access tightens or adverse events occur.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €1.80 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €54.84M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Jun 02, 2026 which is in 35 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
Currently, no data Available
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Undervalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
-337.77%
Trailing 12-Months
Asset Growth
-25.24%
Trailing 12-Months
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
B.R.A.I.N. Biotechnology Research and Information Network (BNN) Earnings & Revenues
BNN Stock 12 Month Forecast
Average Price Target
€5.00
▲(100.00% Upside)